HIGHLIGHTS
- who: Report et al. from the Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, USA Internal Medicine, Michigan State have published the article: Review began 06/22/2021 Review ended 07/09/2021 Published 07/16/2021 © Copyright, in the Journal: (JOURNAL) of July/16,/2021
- what: Dabrafenib and trametinib are novel targeted therapies for BRAF V600E mutant NSCLC.
SUMMARY
In the past decade, lung cancer has not only occupied a prominent place among the most common cancers, but it is also the leading cause of cancer death. This significantly high . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.